Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RAS protein inhibitors - Qualigen Therapeutics

Next Previous
Drug Profile

Research programme: RAS protein inhibitors - Qualigen Therapeutics

Alternative Names: Pan-RAS; RAS-F - Qualigen Therapeutics

Latest Information Update: 29 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Louisville
  • Developer Qualigen Therapeutics; University of Louisville
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein-protein interaction inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Oct 2025 RAS protein inhibitors are still in Preclinical trials in Solid tumours in USA (Qualigen Therapeutics pipeline, October 2025)
  • 10 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours released by Qualigen Therapeutics
  • 08 Apr 2024 Qualigen Therapeutics has patents pending for the Pan-RAS inhibitors in USA, Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Mexico, Russia and South Africa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top